-
Sign In
- Sony Biotechnology
- Sony Biotechnology
Microbial biotechnology is enabling a wide range of applications to address pressing global challenges in medicine, agriculture, manufacturing, and the environment. Learn how the SH800 Cell Sorter's microfluidic chip-based technology is accelerating solutions in these areas.
Learn about the strategies for developing a robust and gentle immune cell enrichment pipeline and the involvement of adaptive immunity in neurodegenerative diseases.
Professor David Liu’s groundbreaking research laid the foundation for the development of CRISPR-based prime editing technology. Discover how the SH800 cell sorter contributed to these pioneering studies by facilitating the selection of stable clone cell lines.
Sony hosted a panel discussion at International Society for Cell and Gene Therapy (ISCT) 2023 where we had distinguished panelists take part in a roundtable discussion on strategies for managing factors affecting cell therapy efficacy.
Sony Biotechnology shared the stage with scientific leaders from Sangamo Therapeutics, France, working on development of a proprietary CAR-Treg manufacturing process, at Advanced Therapeutics Week event in Miami in early 2023.
Learn how the FACS Core Facility at Aarhus University in Denmark, uses a variety of state-of-the-art instruments, including an ID7000 Spectral Cell Analyzer for high-parameter workflows, the factors that went into choosing the system, and the impact on everyday workflows.
Learn how one lab has been using cell sorting to support the successful development of a new technology that combines yeast surface display and orthogonal replication for rapid discovery and engineering of antibodies.
Cardiopulmonary diseases represent a significant health burden for many countries around the world. It is therefore vital to accelerate research toward the development of new therapies to treat these diseases. In this article, we talk to researchers at Queen’s University, Ontario, Canada, about the new Queen’s CardioPulmonary Unit (QCPU) core facility and research center, and how studying endothelial dysfunction, mitochondrial biology, and specific gene mutations is improving the understanding of the molecular factors influencing diseases of the lung vasculature, such as pulmonary arterial hypertension (PAH).
In their quest for answers, Dr. Moshe Sade-Feldman’s team at the Translational Cancer Immunology (TCI) laboratory at Massachusetts General Hospital (MGH), analyzes real-life data from patients treated with immunotherapies. Learn how the team used single-cell profiling to probe the role played by immune cells in patient tumors in the development of the response to cancer therapy.
Dr. Chris Emig, Founder and Chief Executive of Augmenta Bioworks The B-cell receptor repertoire can now be queried by next generation sequencing (NGS) at a scale that enables the rapid collection of millions of antibody sequences from any given individual. The resulting pool of rationally selected antibodies gives researchers access to a comprehensive database of antigen-specific binders and increases the chances of identifying the best antibody sequences. The growing volume of such NGS antibody repositories opens opportunities for alternative methods of therapeutic antibody discovery. Augmenta Bioworks, a biotechnology company headed by Chris Emig, PhD, Co-Founder and Chief Executive Officer, is actively engaged in the discovery of new therapeutics by harnessing the most powerful force in the fight against disease—natural human immunity. This group has developed a novel strategy called the DeepGrid™ platform, which combines single-cell sorting with RNA sequencing to pinpoint the protective immune response of individuals and translate these discoveries into therapies. Dr. Emig explains, "We’re currently working on immune profiling and antibody discovery. Augmenta provides deep insights into human immune repertoires and a technical suite for discovering antibodies of high therapeutic potential. We work with a range of scientists, from academics seeking better insights into human immunity...